

A meta-analysis of the association between obesity and COVID-19

cambridge.org/hyg

Jiao Yang¹ , ZhiYing Ma² and YanChang Lei¹

Original Paper

Cite this article: Yang J, Ma Z, Lei Y (2021). A meta-analysis of the association between obesity and COVID-19. *Epidemiology and Infection* **149**, e11, 1–14. <https://doi.org/10.1017/S0950268820003027>

Received: 14 October 2020
Revised: 26 November 2020
Accepted: 11 December 2020

Key words:

Coronavirus; COVID-19; obesity

Author for correspondence:YanChang Lei, E-mail: leiy2020@163.com

¹Department of Gastroenterology, Liuzhou People's Hospital, WenChang Road 8, LiuZhou 545000, Guangxi Province, China and ²Department of Infectious Disease, Liuzhou People's Hospital, WenChang Road 8, LiuZhou 545000, Guangxi Province, China

Abstract

Owing to limited data, we conducted a meta-analysis to re-evaluate the relationship between obesity and coronavirus-2019 (COVID-19). Literature published between 1 January 2020 and 22 August 2020 was comprehensively analysed, and RevMan3.5 was used for data analysis. A total of 50 studies, including data on 18 260 378 patients, were available. Obesity was associated with a higher risk of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infection (odds ratio (OR): 1.39, 95% confidence interval (CI) 1.25–1.54; $P < 0.00001$) and increased severity of COVID-19 (hospitalisation rate: OR: 2.45, 95% CI 1.78–3.39; $P < 0.00001$; severe cases: OR: 3.74, 95% CI 1.18–11.87; $P = 0.02$; need for intensive care unit admission: OR: 1.30, 95% CI 1.21–1.40; $P < 0.00001$; need for invasive mechanical ventilation: OR: 1.59, 95% CI 1.35–1.88; $P < 0.00001$ and mortality: OR: 1.65, 95% CI 1.21–2.25; $P = 0.001$). However, we found a non-linear association between BMI and the severity of COVID-19. In conclusion, we found that obesity could increase the risk of SARS-CoV2 infection and aggregate the severity of COVID-19. Further studies are needed to explore the possible mechanisms behind this association.

Introduction

In late December 2019, a pneumonia-like disease of unknown aetiology was reported in Wuhan [1], China, which was eventually identified to be caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This pneumonia was renamed coronavirus disease 2019 (COVID-19) and was announced by the World Health Organization (WHO) as a global pandemic on 11 March 2020. As of 8 November 2020, there have been 49 578 590 infected cases and 1 245 717 deaths reported on the WHO dashboard [2]. Clinical manifestations of COVID-19 range from no or mild symptoms to severe pneumonia, acute respiratory distress syndrome (ARDS), or even multiorgan failure and death.

A meta-analysis comprising 18 506 patients investigated the association between diabetes and COVID-19 and found diabetes was associated with a 65% higher risk for death [3]. Other risk factors, such as cardiovascular disease and hypertension, have also been shown to increase the severity of COVID [4–6]. The diseases mentioned above are usually associated with excessive adipose tissue accumulation causing metabolic and inflammatory changes [7–9]. Obesity has been identified as an independent predisposition factor for severe cases of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) infection [10], and a high genetic similarity was observed between SARS-CoV-2 and SARS-CoV (80%) and MERS-CoV (50%) [11]. These data indicate that obesity might be a risk factor for the severity of COVID-19.

One previous study in China showed that only 18.95% of survivors were overweight, and 88.24% of non-survivors had a higher body mass index (BMI) [12]. In Germany, patients with ARDS were more overweight or obese (83%) than those with healthy BMI (42%) [13]. More recently, some meta-analyses showed that obesity was associated with mortality, severity and predicted poor outcome in COVID-19 patients [14–17]. However, there are some limitations to these meta-analyses. First, the number of eligible studies is small, ranging from 9 to 14. Second, the data from other countries are scarce, and most eligible studies are from China and the USA. Third, the definition of obesity is different between Eastern and Western countries. Last, the conclusions of previous meta-analyses may be altered due to the recent emergence of a large number of studies about the association between obesity and COVID-19. Europe and North America, which have the highest prevalence of obesity cases, has become the epicentre of the COVID-19 pandemic [18]. Therefore, it is necessary to re-explore the relationship between obesity and COVID-19, including susceptibility to SARS-Cov-2 infection, which was not analysed in previous meta-analyses and poor outcomes, as we have performed in the meta-analysis presented here.

© The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is included and the original work is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use.

CAMBRIDGE
UNIVERSITY PRESS




Fig. 1. Flow diagram of the literature selection process.

Methods

Research strategy

This meta-analysis was performed following the PRISMA guidelines. A comprehensive search was performed using the PubMed, EMBASE and Cochrane Library databases for literature published between 1 January 2020 and 25 August 2020. The following words were utilised during the search: (COVID-19 or coronavirus or SARS-CoV-2) and (obesity or overweight or body mass index). Reference lists of eligible studies and relevant review articles were screened and evaluated for additional studies that could be used in analyses.

Inclusion and exclusion criteria

Inclusion criteria for the studies in our analyses were as follows:

- (1) Studies published in English
- (2) Studies investigating the association between obesity or overweight and COVID-19.
- (3) Studies including both adults and children diagnosed with COVID-19.
- (4) Cohort studies with prospective or retrospective designs.

Exclusion criteria from analyses were:

Table 1. Baseline characteristics of the eligible studies

Study	Region	Centre(s)	Design	Obesity <i>n</i> %	Total	Male	Age	Outcomes	NOS score
Alkhatib [19]	USA	Single	Retrospective	60.76	158	61	57	ICU admission	7
Argenziano [20]	USA	Single	Retrospective	41.85	1000	596	63 50–75	ICU admission	7
Bello-Chavolla [21]	Mexico	Multiple	Retrospective	16.42	177 133	90 582	42.58	Risk of COVID 19 infection Mortality ICU admission Need of IMV	7
Buckner [22]	USA	Multiple	Retrospective	47.31	105	53	69 23–97	Severe cases	7
Busetto [11]	Italy	Single	Retrospective	31.52	92	57	70.5 ± 13.3	Mortality ICU admission Need of IMV	8
Cai1 [23]	China	Single	Retrospective	NA	298	145	47 33–61	Severe cases	7
Cai2 [24]	China	Single	Retrospective	10.70	383	183	48.4	Severe cases	7
Caussy [25]	France	Single	Retrospective	25	340	NA	NA	Severe cases	7
Chand [26]	USA	Multiple	Retrospective	54.33	300	182	57.8 ± 12.2	Mortality	8
Chao [27]	USA	Single	Retrospective	26.09	46	31	13.1 0.4–19.3	ICU admission	7
Cummings [29]	USA	Double	Prospective	46.30	257	171	62 51–72	Mortality	8
Czernichow [28]	France	Multiple	Prospective	21.81	5795	3791	NA	Mortality	8
Docherty [30]	UK	Multiple	Prospective	10.48	20 133	12 068	73 58–82	Mortality	8
Duanmu [31]	USA	Single	Retrospective	22	100	56	45 32–65	Hospitalisation	7
Escalera-Antezana [32]	Bolivia	Single	Retrospective	5.61	107	55	43.9 ± 17.6	Mortality	8
Gao [33]	China	Multiple	Retrospective	50	150	94	48	Severe cases	7
Gerwen [34]	USA	Multiple	Retrospective	28.95	3703	2049	56.8 ± 18.2	Mortality Need of IMV Hospitalisation	8
Giannouchos [35]	Mexico	Multiple	Retrospective	16.7	236 439	120 347	42.5 ± 16.9	Risk of COVID-19 infection Hospitalisation	7
Goyal1 [36]	USA	Single	Retrospective	34.60	393	238	62.2 48.6–73.7	Need of IMV	7
Goyal2 [37]	USA	Double	Retrospective	31.12	1687	1004	66.5 53.7–77.2	Mortality	8
Giracomelli [38]	Italy	single	Prospective	16.31	233	161	61 50–72	Mortality	8

(Continued)

Table 1. (Continued.)

Study	Region	Centre(s)	Design	Obesity <i>n</i> %	Total	Male	Age	Outcomes	NOS score
Hajifathalian [39]	USA	Double	Retrospective	35.97	770	468	63.5 ± 17	Mortality ICU admission Need of IMV	8
Halasz [40]	Italy	Single	Retrospective	19.83	242	194	64 56–71	Mortality	8
Hamer [41]	UK	Multiple	Prospective	23.84	334 329	152 162	NA	Risk of COVID-19 infection	7
Hu [42]	China	Single	Retrospective	4.02	323	166	61 23–91	Severe cases	7
Hur [43]	USA	Multiple	Retrospective	53.29	486	271	59 47–69	Need of IMV	7
Jung [44]	South Korea	Multiple	Retrospective	NA	18 940	7185	53.7 ± 13.8	Risk of COVID-19 infection	7
Kalligeros [45]	USA	Single	Retrospective	47.57	103	63	60 50–72	ICU admission Need of IMV	7
Killerby [46]	Atlanta	Multiple	Retrospective	42.75	531	228	51.63	Hospitalisation	7
Kim [47]	USA	Multiple	Retrospective	46.33	2491	1326	62 50–75	ICU admission	7
Klang [48]	USA	Single	Retrospective	36.14	3406	1961	65.9	Mortality	8
Lighter [49]	USA	Single	Retrospective	37.90	3615	NA	NA	Hospitalisation ICU admission	7
Lodigiani [67]	Italy	Single	Retrospective	23.97	388	264	66	ICU admission	7
Lusignan [50]	UK	Multiple	Retrospective	21.70	3802	1612	NA	Risk of COVID-19 infection	7
Monterio [51]	USA	Single	Retrospective	35.71	112	74	61 45–74	Need of IMV	7
Nakeshbandi [52]	USA	Single	Retrospective	42.66	504	263	68 ± 15	Mortality Need of IMV	8
Ong [53]	Singapore	Single	Retrospective	NA	91	51	54.92	Mortality ICU admission Need of IMV	7
Oriz-Brizuela [54]	Mexico	Single	Prospective	21.68	309	183	43 33–54	Hospitalisation ICU admission	7
Palaiodimos [55]	USA	Single	Retrospective	NA	200	98	64 50–73.5	Mortality Need of IMV	8
Parra-Bracamonte [56]	Mexico	Multiple	Retrospective	19.92	142 690	79 280	45 34–57	Mortality	8
Petrilli [57]	USA	Multiple	Retrospective	26.81	4103	2072	52 36–65	Hospitalisation Severe cases	7
Price-Haywood [58]	USA	Single	Retrospective	49.61	3481	1394	54	Hospitalisation	7
Shah [59]	USA	Multiple	Retrospective	66.48	522	347	63 50–72	Mortality	8

Author	Country	Study Design	Study Type	Retrospective	NA	124	90	60 51–70	Need of IMV	7
Simonnet [60]	France	Single	Retrospective	NA	124	90	60 51–70	Need of IMV	7	
Soares [61]	Brazil	Multiple	Retrospective	5.57	10 713	4804	NA	Hospitalisation	7	
Suleyman [62]	USA	Multiple	Retrospective	56.59	463	204	57.5 ± 16.8	Hospitalisation ICU admission Need of IMV	7	
Williamson [63]	UK	Multiple	Retrospective	21.82	17 278 392	8 630 403	NA	Mortality	8	
Wu [64]	China	Multiple	Retrospective	NA	280	151	43.12 ± 19.02	Severe cases	7	
Zachariah [65]	USA	Single	Retrospective	22	50	27	9.9	Severe cases	7	
Zheng [66]	China	Multiple	Retrospective	68.18	66	49	47	Severe cases	7	

IMV, invasive mechanical ventilation; ICU, intensive care unit; NA, not available; NOS, Newcastle–Ottawa quality assessment scale.

- (1) Review articles, letters or commentaries.
- (2) Duplicate studies.
- (3) Studies in which data were not available.

Data assessment

Two individual authors (Jiao Yang and ZhiYing Ma) independently extracted the following information: study design, age, gender, susceptibility to COVID-19, the severity of COVID-19 (need for hospitalisation, severe cases, need for intensive care unit (ICU) admission, need for invasive mechanical ventilation (IMV) and mortality). Severe COVID-19 was defined according to the American Thoracic Society guidelines.

Statistical analysis

RveMan5.3 (Cochrane Collaboration) was used to analyse data with associated odds ratios (OR) and corresponding 95% confidence intervals (CIs). The generic inverse variance approach was used for the meta-analysis. A $P < 0.05$ was identified as statistically significant. The I^2 statistic was used to assess the heterogeneity among the studies analysed. An $I^2 > 50\%$ or $P < 0.1$ indicated heterogeneity, for which the random-effects model was utilised. Otherwise, the fixed-effects model was used. In addition, publication bias was evaluated through visual inspections of funnel plots, and the quality of eligible studies was assessed using the Newcastle–Ottawa Quality Assessment Scale.

Results

Study characteristics

A total of 50 studies [11, 19–67] that included 18 260 378 subjects were eligible for the meta-analysis. Out of these 50 studies, 44 were retrospective and 6 were prospective cohort studies. Twenty-five studies were conducted in the USA, 6 in China, 4 in Italy, 4 in the UK, 4 in Mexico, 3 in France and 1 in Brazil, Singapore, South Korea and Bolivia. The incidence of obesity, defined as BMI ≥ 30 , varied from 5.57% to 68.48% in this meta-analysis. Detailed search strategies and characteristics of eligible studies are presented in Fig. 1 and Table 1, respectively. The Newcastle–Ottawa Quality Assessment Scale scores for all included studies were equal to or more than 6, as shown in Table 1, which is acceptable for a meta-analysis.

Outcomes

Risk of COVID-19

Five studies involving 753 597 cases mentioned the association between obesity and the risk of SARS-CoV2 infection. We used the random-effects model for analysis due to a high heterogeneity ($P < 0.00001$ and $I^2 = 92\%$) between studies. This model suggested that obese subjects had a higher risk of SARS-CoV2 infection as compared to those without obesity (OR: 1.39; 95% CI 1.25–1.54; $P < 0.00001$) (Fig. 2).

Severity of COVID-19

Hospital admission: We conducted a stratified analysis to assess the relationship between BMI ranges and the need for hospital admission in patients with COVID-19. Patients with a BMI 25–29.9, BMI ≥ 30 and BMI ≥ 35 had higher rates of hospital admission than those with a BMI < 25 (OR: 2.09, 95% CI 1.22–3.60, P :




Fig. 2. Forrest plot depicting the risk of COVID-19.

0.007; OR: 2.45, 95% CI 1.78–3.39, $P < 0.00001$ and OR: 2.63, 95% CI 1.55–4.47, $P: 0.0003$, respectively) (Fig. 3). However, no significant increases in hospital admission rates were found for patients with a BMI between 30 and 34.9 (OR: 1.10, 95% CI 0.88–1.37, $P: 0.4$) than those with a healthy weight, as shown in Figure 3.

Severe cases: Ten studies reported on the association between BMI and severe cases of COVID-19. Four trials comprising 794 patients showed that those with severe diseases had a higher BMI than those with mild disease (OR: 1.18, 95% CI 1.09–1.27, $P < 0.0001$) (Fig. 3). In addition, patients with a BMI ≥ 30 had a higher prevalence of severe cases than those with BMI < 30 (OR: 3.74, 95% CI 1.18–11.87, $P: 0.02$) (Fig. 3).

ICU admission: Eleven studies evaluated the incidence of ICU care in COVID-19 patients. A stratified analysis on the association of the different BMI classes and the rate of ICU admission was conducted. Patients with COVID-19 with a BMI ≥ 30 , BMI ≥ 35 and ≥ 40 had a higher probability of requiring ICU admission than those with a BMI < 30 (OR: 1.30, 95% CI 1.21–1.40, $P < 0.00001$; OR: 1.86, 95% CI 1.31–2.63, $P: 0.0005$ and OR: 1.96, 95% CI 1.27–3.02, $P: 0.002$, respectively), as shown in Figure 4. However, patients with a BMI ≥ 25 or BMI 30–34.9 showed no significantly higher rate of ICU admission than those with a BMI < 25 or BMI < 30 (OR: 3.10, 95% CI 0.76–12.61, $P: 0.11$ and OR: 1.44, 95% CI 0.74–2.81, $P: 0.28$, respectively) (Fig. 4).

IMV: Thirteen studies assessed the association between BMI and the need for IMV in patients with COVID-19. We compared the requirement of IMV in different BMI groups and found that the need for IMV was notably raised in patients with a BMI ≥ 25 , BMI ≥ 30 , BMI ≥ 35 and BMI ≥ 40 compared to those with a BMI < 25 (OR: 1.40, 95% CI 1.13–1.73, $P: 0.002$; OR: 1.59, 95% CI 1.35–1.88, $P < 0.00001$; OR: 5.22, 95% CI 2.46–11.07, $P < 0.0001$ and OR: 1.97, 95% CI 1.24–3.12, $P: 0.004$, respectively) (Fig. 5).

Mortality

Fourteen studies investigated the association between different BMI categories and mortality. As shown in Figure 6, the mortality was significantly higher in patients with a BMI ≥ 30 , BMI 35–39.9 and BMI ≥ 40 than those with a BMI < 30 (OR: 1.65, 95% CI 1.21–2.25, $P: 0.001$; OR: 1.91, 95% CI 1.04–3.49, $P: 0.04$ and OR: 1.71, 95% CI 1.32–2.22, $P < 0.0001$, respectively). Nevertheless, patients with a BMI between 25 and 29.9 and a BMI between 30 and 34.9 did not have a statistically significant higher risk of mortality than those with a BMI < 25 (OR: 1.10, 95% CI 0.84–1.45, $P: 0.48$ and OR: 1.38, 95% CI 0.94–2.04, $P: 0.1$) (Fig. 6).

Publication bias

The publication bias was assessed using a visual funnel plot. No obvious publication bias was found for the outcomes assessed

((a) risk of COVID-19; (b) hospital admission; (c) severe cases; (d) ICU admission; (e) need of IMV) as shown in Figure 7.

Discussion


Our study found obesity increased the prevalence of SARS-CoV2 infection and the severity of COVID-19 (as assessed by the need for hospitalisation, severe cases, need for ICU admission, need for IMV and mortality). Patients with overweight presented with a higher rate of hospitalisation and higher requirement of IMV. However, a non-linear association between BMI and the severity of COVID-19 was found. To our knowledge, this study is the largest meta-analysis conducted so far to comprehensively explore the association between obesity and COVID-19.

Yates *et al.* analysed UK biobank data and found that overweight and obese patients were at a higher risk of getting the SARS-CoV-2 in a dose–response manner. Compared to a healthy weight, overweight, obese and severely obese (BMI ≥ 35) subjects had a 1.31-, 1.55-, or 1.57-fold higher probability of SARS-CoV-2 positivity [68]. Chadeau-Hyam *et al.* reported that severe obesity is independently associated with the risk of obtaining COVID-19 with an odds ratio > 1.05 by analysing the data from Public Health England [69]. In our meta-analysis, patients with a BMI ≥ 30 had a 1.39 times higher chance of having COVID-19 than those with a healthy weight, which was in line with previous studies.


Obesity was the most prevalent condition in inpatients with COVID-19 aged 18–49 years in a study conducted by Garg *et al.* [70], which suggests that obesity may increase the hospitalisation rate of patients with COVID-19. A prospective study in New York revealed that an increase in BMI (e.g. BMI > 40 with 2.6 odds) in patients with COVID-19 was strongly associated with hospital admission [71]. In our meta-analysis, the odds ratios for hospitalisation rate were 2.09, 2.45 and 2.63 for patients with a BMI of 25–29.9, ≥ 30 and ≥ 35 , respectively. This suggests that a higher BMI predicts a higher hospitalisation rate for patients with COVID-19. However, no significant association between patients with a BMI 30–34.9 and hospital admission was found, which may be attributed to the limited number of eligible studies reporting on this BMI group.

A study conducted in China reported that there were no patients with underweight who developed severe COVID-19, and that obese patients progressed to severe cases (39% in the obese group, 29.3% in the overweight group and 19.2% in the healthy weight group) [23]. An observational study revealed that severely ill patients had a higher BMI (mean, 24.78 vs. 23.20) than patients with non-severe disease [72]. This indicated that a higher BMI increased the chance of COVID-19 severity. Here, we found that BMI was a major influential factor for COVID-19 progression to severity (OR: 1.18). In addition, obese patients


a: BMI 25–29.9 and hospital admission




b: BMI ≥ 30 and hospital admission




c: BMI 30–34.9 and hospital admission



d: BMI ≥ 35 and hospital admission



e: BMI and severe cases



f: BMI ≥ 30 and severe cases






Fig. 3. Forrest plot showing the severity of COVID-19: (a) BMI 25–29.9 and hospital admission, (b) BMI ≥ 30 and hospital admission, (c) BMI 30–34.9 and hospital admission, (d) BMI ≥ 35 and hospital admission, (e) BMI and severe cases, (f) BMI ≥ 30 and severe cases.

a: BMI \geq 25 and ICU admissionb: BMI \geq 30 and ICU admission

c: BMI 30-34.9 and ICU admission




d: BMI \geq 35 and ICU admissione: BMI \geq 40 and ICU admission

Fig. 4. Forrest plot showing the severity of COVID-19: (a) BMI \geq 25 and ICU admission, (b) BMI \geq 30 and ICU admission, (c) BMI 30–34.9 and ICU admission, (d) BMI \geq 35 and ICU admission, (e) BMI \geq 40 and ICU admission.

were 3.74 times more likely to get severe COVID-19 than those with BMI < 30. These data together indicate that obesity or a high BMI increases the chance of severe cases.

A large international multicentre study showed that the mean BMI of critically ill patients was 28.1, and the overall prevalence of

obesity was 37.5% [73]. Cai *et al.* also reported that patients with a BMI \geq 24 (OR = 1.258, $P = 0.005$) were more likely to be admitted to the ICU [74]. However, we failed to find a positive association between overweight and the risk of ICU admission. However, patients with BMI \geq 30 and BMI \geq 35 showed a 1.30- and





a; BMI \geq 25 and need for IMVb: BMI \geq 30 and need for IMVc: BMI \geq 35 and need for IMVd: BMI \geq 40 and need for IMV

Fig. 5. Forrest plot showing the severity of COVID-19: (a) BMI \geq 25 and need for IMV, (b) BMI \geq 30 and need for IMV, (c) BMI \geq 35 and need for IMV, (d) BMI \geq 35 and need for IMV, (e) BMI \geq 40 and need for IMV.


1.86-fold odds of requiring ICU admission compared to those with a BMI $<$ 30. Therefore, there might be a positive correlation between the severity of obesity and the risk of ICU admission. Surprisingly, patients with BMI 30–34.9 presented no significant risk of ICU admission compared to those with BMI $<$ 30, which should be confirmed in future studies.

Simonnet *et al.* reported data from the Lille University centre, showing that severe obesity (BMI \geq 35) was associated with a higher requirement for mechanical ventilation compared to patients with a healthy weight (81.8% vs. 41.9%) [60]. In Singapore, Ong *et al.* found that a BMI \geq 25 was significantly associated with mechanical ventilation (OR 1.16) [53]. Moreover, Chetboun *et al.* reported that the relationship between BMI and the risk of the need for IMV was linear, and the odds were 3.06-fold higher in patients with a BMI \geq 40 [73]. In our meta-analysis, the odds of IMV risk in patients with BMI \geq 25 and BMI \geq 30 were 1.40 and 1.59 times higher than those with


BMI $<$ 25 and BMI $<$ 30. For severely obese patients (BMI \geq 35) diagnosed with COVID-19, the odds of requiring IMV were 5.22. However, for morbidly obese patients (BMI \geq 40), the odds were 1.97. It appears that no significant linear relationship exists between higher BMI and the requirement of IMV, which is in contrast to previous studies [73].

A retrospective analysis of 112 patients with COVID-19 showed that 88.2% of non-survivors had a BMI \geq 25 compared to 18.8% of survivors [75]. Asare *et al.* showed that 733 of 1930 deaths from COVID-19 were contributed to obesity alone in patients without reported comorbid conditions such as hypertension and cardiovascular disease [76]. On the contrary, no difference in the mortality rates was found between those with obesity and the non-obesity arm [77]. In the study, patients with a BMI between 25 and 29.9 had no significant higher risk of mortality compared to those with a BMI $<$ 25. However, the odds ratio of mortality in patients with COVID-19 with a BMI \geq 30, BMI 35–39.9 and BMI \geq 40


a: BMI 25-29.9 and mortality




b: BMI ≥ 30 and mortality



c: BMI 30-34.9 and mortality



d: BMI 35-39.9 and mortality



e: BMI ≥ 40 and mortality




Fig. 6. Forrest plot showing mortality caused by COVID-19: (a) BMI 25–29.9 and mortality, (b) BMI≥30 and mortality, (c) BMI 30–34.9 and mortality, (d) BMI 35–39.9 and mortality, (e) BMI≥40 and mortality.

were 1.65, 1.91 and 1.71, respectively. This suggests a positive relationship between obesity and mortality in patients with COVID-19. Surprisingly, patients with a BMI between 30 and 34.9 did not have a higher mortality risk.

The mechanism behind the finding that overweight or obesity may aggravate COVID-19 remains to be elucidated. Possible mechanisms have been presented in previous studies. Ziegler *et al.* reported that angiotensin-converting enzyme 2 (ACE2)




Fig. 7. Funnel plot of various outcomes: (a) risk of COVID-19, (b) hospital admission, (c) severe cases, (d) ICU admission, (e) the need for IMV.

facilitates cellular entry of SARS-CoV-2 [78]. Higher concentrations of ACE2 are not only expressed on lung tissues [79, 80], such as bronchial smooth muscle cells and alveolar epithelium, but also on extrapulmonary tissues, specifically the heart, kidney, ileum, jejunum and adipose tissues [79, 81]. The ACE2 gene-expression profile was assessed in the HCCDB gene-expression database, demonstrating that ACE2 gene expression was higher in

human subcutaneous and visceral adipose tissue than in human lung tissue [82], indicating excess adiposity may induce higher susceptibility of SARS-CoV-2 infection and higher infection severity in patients with COVID-19. Moreover, studies show that obesity disrupts the immune system, limiting its capacity to deal with a new virus like SARS-CoV-2 [83]. In severe cases, patients may have a cytokine storm, characterised by the overproduction of IL-6,

TNF- α , monocyte chemoattractant protein-1 and leptin, resulting in an increased risk of vascular hyperpermeability and multiorgan failure [84, 85]. Besides, respiratory physiology is altered in patients with obesity, resulting in decreased functional residual capacity and expiratory reserve volume, leading to subsequent ventilation–perfusion abnormalities and hypoxaemia [86, 87]. In addition, obesity has been associated with a high risk of developing venous thromboembolism [88], which is frequently reported in COVID-19 cases and is correlated with a poor prognosis [89].

There are some limitations of this study that should be noted. First, most studies included here were retrospective and were conducted in the USA. Additional prospective studies from other countries should be performed to validate the results presented here. Second, patients suffering from a SARS-CoV2 infection with BMI 30–34.9 presented no significant differences in hospitalisation rates, the need for ICU admission, or mortality compared with those without obesity. This might be attributed to the few eligible studies for this group of patients, and further studies are required to confirm these data. Third, we may have excluded some studies from this meta-analysis that reported outcomes related to obesity without mentioning the terms (obesity or overweight or body mass index). Last, experimental parameters such as c-reactive protein, interleukin-6, and coagulation index were not evaluated in this study.

In conclusion, obesity might increase the risk of SARS-Cov2 infection and aggravate the severity of COVID-19.

Conflict of interest. None declared.

Data availability statement. The data that support the findings of this study are openly available in at <http://doi.org/10.1017/S0950268820003027>.

References

- Zhu N et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine* **382**, 727–733.
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int/> (Accessed 8 November 2020).
- Palaiodimos L et al. (2020) Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients. *Hormones (Athens)*. Published online: 29 Oct 2020. doi: 10.1007/s42000-020-00246-2.
- Zheng Z et al. (2020) Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. *Journal of Infection* **81**, e16–e25.
- Zhou F et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* **395**, 1054–1062.
- Nancy C et al. (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. *Morbidity and Mortality Weekly Report* **69**, 382–386.
- Huttunen R and Syrjanen J (2013) Obesity and the risk and outcome of infection. *International Journal of Obesity (Lond)* **37**, 333–340.
- Malavazos AE et al. (2020) Targeting the adipose tissue in COVID-19. *Obesity (Silver Spring)* **28**, 1178–1179.
- Seravalle G GG (2017) Obesity and hypertension. *Pharmacological Research* **122**, 1–7.
- Van Kerkhove MD et al. (2011) Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. *PLOS Medicine* **8**, e1001053.
- Busetto L et al. (2020) Obesity and COVID-19: an Italian snapshot. *Obesity (Silver Spring)* **28**, 1600–1605.
- Peng YD et al. (2020) Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. *Zhonghua Xin Xue Guan Bing Za Zhi* **48**, E004.
- Dreher M et al. (2020) The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. *Deutsches Arzteblatt International* **117**, 271–278.
- Foldi M et al. (2020) Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis. *Obesity Reviews* **21**, e13095.
- Malik VS et al. (2020) Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis. *Environmental Science and Pollution Research* **27**, 42115–42123.
- Pranata R et al. (2020) Body mass index and outcome in patients with COVID-19: a dose-response meta-analysis. *Diabetes & Metabolism*. Published online: 29 Jul 2020. doi: 10.1016/j.diabet.2020.07.005.
- Yang J et al. (2020) Obesity aggravates COVID-19: a systematic review and meta-analysis. *Journal of Medical Virology*. Published online: 30 Jun 2020. doi: 10.1002/jmv.26237.
- World Health Organization. Prevalence of obesity among adults, BMI \geq 30, age-standardized estimates by WHO region. <https://apps.who.int/gho/data/viewmain/REGION2480A?lang=en> (Accessed 1 November 2020).
- Alkhatib AL et al. (2020) BMI is associated with coronavirus disease 2019 intensive care unit admission in African Americans. *Obesity (Silver Spring)* **28**, 1798–1801.
- Argenziano MG et al. (2020) Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. *British Medical Journal* **369**, m1996.
- Bello-Chavolla OY et al. (2020) Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. *Journal of Clinical Endocrinology & Metabolism* **105**, dgga346.
- Buckner FS et al. (2020) Clinical features and outcomes of 105 hospitalized patients with COVID-19 in Seattle, Washington. *Clinical Infectious Diseases* **71**, 2167–2173.
- Cai Q et al. (2020) Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. *Diabetes Care* **43**, 1392–1398.
- Cai Q et al. (2020) COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* **75**, 1742–1752.
- Caussy C et al. (2020) Prevalence of obesity among adult inpatients with COVID-19 in France. *The Lancet Diabetes & Endocrinology* **8**, 562–564.
- Chand S et al. (2020) COVID-19-associated critical illness-report of the first 300 patients admitted to intensive care units at a New York City Medical Center. *Journal of Intensive Care Medicine* **35**, 963–970.
- Chao JY et al. (2020) Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York City. *Journal of Pediatrics* **223**, 14–19.e12.
- Czernichow S et al. (2020) Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795 patients. *Obesity (Silver Spring)*. Published online: 20 Aug 2020. doi: 10.1002/oby.23014.
- Cummings MJ et al. (2020) Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. *The Lancet* **395**, 1763–1770.
- Docherty AB et al. (2020) Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. *British Medical Journal* **369**, m1985.
- Duanmu Y et al. (2020) Characteristics of emergency department patients With COVID-19 at a single site in Northern California: clinical observations and public health implications. *Academic Emergency Medicine* **27**, 505–509.
- Escalera-Antezana J et al. (2020) Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) in Bolivia: an analysis of the first 107 confirmed cases. *Le Infezioni in Medicina* **28**, 238–242.
- Gao F et al. (2020) Obesity is a risk factor for greater COVID-19 severity. *Diabetes Care* **43**, e72–e74.

34. **van Gerwen M et al.** (2020) Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. *Journal of Medical Virology*. Published online: 24 Jul 2020. doi: 10.1002/jmv.26337.
35. **Giannouchos TV et al.** (2020) Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. *European Respiratory Journal*. doi: 10.1183/13993003.02144-2020.
36. **Goyal P et al.** (2020) Clinical characteristics of Covid-19 in New York City. *New England Journal of Medicine* **11**, 2372–2374.
37. **Goyal P et al.** (2020) Obesity and COVID-19 in New York City – a retrospective cohort study. *Annals of Internal Medicine* **173**, 855–858.
38. **Giacomelli A et al.** (2020) 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. *Pharmacological Research* **158**, 104931.
39. **Hajifathalian K et al.** (2020) Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York City. *Obesity (Silver Spring)* **28**, 1606–1612.
40. **Halasz G et al.** (2020) Obesity, overweight and survival in critically ill patients with SARS-CoV-2 pneumonia: is there an obesity paradox? Preliminary results from Italy. *European Journal of Preventive Cardiology*. Published online: 7 Jul 2020. doi: 10.1177/2047487320939675:2047487320939675.
41. **Hamer M et al.** (2020) Overweight, obesity, and risk of hospitalization for COVID-19: a community-based cohort study of adults in the United Kingdom. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 21011–21013.
42. **Hu L et al.** (2020) Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. *Clinical Infectious Diseases*. Published online: 3 May 2020. doi: 10.1093/cid/ciaa539.
43. **Hur K et al.** (2020) Factors associated with intubation and prolonged intubation in hospitalized patients with COVID-19. *Otolaryngology Head and Neck Surgery* **163**, 170–178.
44. **Jung CY et al.** (2020) Association between body mass Index and risk of COVID-19: a nationwide case-control study in South Korea. *Clinical Infectious Diseases*. Published online: 25 Aug 2020. doi: 10.1093/cid/ciaa1257.
45. **Kalligeros M et al.** (2020) Association of obesity with disease severity among patients with coronavirus disease 2019. *Obesity (Silver Spring)* **28**, 1200–1204.
46. **Killerby ME et al.** (2020) Characteristics associated with hospitalization among patients with COVID-19 – metropolitan Atlanta, Georgia, March–April 2020. *Morbidity and Mortality Weekly Report* **69**, 790–794.
47. **Kim L et al.** (2020) Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the U.S. Coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). *Clinical Infectious Diseases*. Published online: 16 July 2020. doi: 10.1093/cid/ciaa1012.
48. **Klang E et al.** (2020) Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. *Obesity (Silver Spring)* **28**, 1595–1599.
49. **Lighter J et al.** (2020) Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. *Clinical Infectious Diseases* **71**, 896–897.
50. **Lusignan SD et al.** (2020) Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of general practitioners research and surveillance centre primary care network: a cross-sectional study. *The Lancet Infectious Diseases* **20**, 1034–1042.
51. **Monteiro ACC et al.** (2020) Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19 respiratory failure – a retrospective, observational cohort study. *MedRxiv*. Published online: 14 Aug 2020. doi: 10.1101/2020.08.12.20173849.
52. **Nakeshbandi M et al.** (2020) The impact of obesity on COVID-19 complications: a retrospective cohort study. *International Journal of Obesity* **44**, 1832–1837.
53. **Ong SWX et al.** (2020) Association of higher body mass index (BMI) with severe coronavirus disease 2019 (COVID-19) in younger patients. *Clinical Infectious Diseases*. Published online: 8 May 2020. doi: 10.1093/cid/ciaa548.
54. **Ortiz-Brizuela E et al.** (2020) Clinical and epidemiological characteristics of patients diagnosed with Covid-19 in a tertiary care center in Mexico City: a prospective cohort study. *Revista de Investigación Clínica* **72**, 165–177.
55. **Palaodimos L et al.** (2020) Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism: Clinical and Experimental* **108**, 154262.
56. **Parra-Bracamonte GM et al.** (2020) Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large dataset from Mexico. *Annals of Epidemiology*. Published online: 14 Aug 2020. doi: 10.1016/j.annepidem.2020.08.005.
57. **Petrilli C et al.** (2020) Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York city. *Medicine*. Published online: 11 April 2020. doi: 10.1101/2020.04.08.20057794.
58. **Price-Haywood EG et al.** (2020) Hospitalization and mortality among black patients and white patients with Covid-19. *New England Journal of Medicine* **382**, 2534–2543.
59. **Shah P et al.** (2020) Demographics, comorbidities and outcomes in hospitalized Covid-19 patients in rural southwest Georgia. *Annals of Medicine* **52**, 354–360.
60. **Simonnet A et al.** (2020) High prevalence of obesity in severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity (Silver Spring)* **28**, 1195–1199.
61. **Soares RCM et al.** (2020) Risk factors for hospitalization and mortality due to COVID-19 in Espirito Santo State, Brazil. *American Journal of Tropical Medicine and Hygiene* **103**, 1184–1190.
62. **Suleyman G et al.** (2020) Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. *JAMA Network Open* **3**, e2012270.
63. **Williamson EJ et al.** (2020) Factors associated with COVID-19-related death using OpenSAFELY. *Nature* **584**, 430–436.
64. **Wu J et al.** (2020) Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). *Journal of International Medicine* **288**, 128–138.
65. **Zachariah P et al.** (2020) Epidemiology, clinical features, and disease severity in patients with Coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. *JAMA Pediatrics* **174**, e202430.
66. **Zheng KI et al.** (2020) Letter to the editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolism: Clinical and Experimental* **108**, 154244.
67. **Lodigiani C et al.** (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research* **191**, 9–14.
68. **Yates T et al.** (2020) Obesity and risk of COVID-19 – analysis of UK biobank. *Primary Care Diabetes* **14**, 566–567.
69. **Chadeau-Hyam M et al.** (2020) Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data. *International Journal of Epidemiology*. Published online: 20 Aug 2020. doi: 10.1093/ije/dyaa134.
70. **Garg S et al.** (2020) Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID. *Morbidity Mortality Weekly Report* **69**, 458–464.
71. **Petrilli C et al.** (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study. *British Medical Journal* **369**, m1996.
72. **Chen QQ et al.** (2020) Clinical characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou. *Infection* **48**, 543–551.
73. **Chetboun M et al.** (2020) Association of body mass index and other metabolic risk factors with pneumonia outcomes in critically ill patients with coronavirus disease-19: an international multicenter retrospective cohort study. *SSRN Electronic Journal*.
74. **Cai SH et al.** (2020) Association between obesity and clinical prognosis in patients infected with SARS-CoV-2. *Infectious Diseases of Poverty* **9**, 80.
75. **Peng Y et al.** (2020) Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. *Zhonghua Xin Xue Guan Bing Za Zhi* **48**, 450–455.

76. **Asare S *et al.*** (2020) Higher obesity trends Among African Americans are associated with increased mortality in infected COVID-19 patients within the city of Detroit. *SN Comprehensive Clinical Medicine*. Published online: 30 June 2020. doi: 10.1007/s42399-020-00385-y.
77. **Moriconi D *et al.*** (2020) Obesity prolongs the hospital stay in patients affected by COVID-19 and may impact on SARS-COV-2 shedding. *Obesity Research & Clinical Practice* **14**, 205–209.
78. **Ziegler CGK *et al.*** (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. *Cell* **181**, 1016–1035.
79. **Zou X *et al.*** (2020) Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers of Medicine* **14**, 185–192.
80. **Verdecchia P *et al.*** (2020) The pivotal link between ACE2 deficiency and SARS- CoV-2 infection. *European Journal of International Medicine* **76**, 14–20.
81. **Hamming I *et al.*** (2004) Issue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *Journal of Pathology* **203**, 631–637.
82. **Al-Benna S** (2020) Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. *Obesity Medicine* **19**, 100283.
83. **Milner JJ *et al.*** (2012) The impact of obesity on the immune response to infection. *Proceedings of the Nutrition Society* **71**, 298–306.
84. **Jose RJ *et al.*** (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respiratory Medicine* **8**, e46–e47.
85. **van der Voort PHJ *et al.*** (2020) Leptin levels in SARS-CoV-2 infection related respiratory failure: a cross-sectional study and a pathophysiological framework on the role of fat tissue. *Heliyon* **6**, e04696.
86. **Bahammam AS SEA-J** (2012) Managing acute respiratory decompensation in the morbidly obese. *Respirology (Carlton, Vic.)* **17**, 759–771.
87. **Zammit C *et al.*** (2010) Obesity and respiratory diseases. *International Journal of General Medicine* **3**, 335–343.
88. **Lorenzet R *et al.*** (2012) Thrombosis and obesity: cellular bases. *Thrombosis Research* **129**, 285–289.
89. **Kyriakoulis KG, *et al.*** (2020) Venous thromboembolism in the era of COVID-19. *Phlebology: The Journal of Venous Disease*. Published online: 10 Sep 2020. doi: 10.1177/0268355520955083.